In Volume 5 No. 11/12 of the euroPLX Business Developer (download from www.europlx.com if you haven’t seen it), there was an interesting article about views of best partnering practices. more »

In only its second year, EBD Group’s partnering event for the medical technology industry, EuroMedtech™, has become the premier destination for emerging innovator companies and start-ups to seek out and secure funding. more »

As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma* is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines. more »

By Susie Slaughter, Slaughter and May

Whatever the economic climate, licences warrant careful drafting since they are generally long-lasting agreements. In the biotechnology arena they also have an important role for both licensors and licensees in demonstrating commercial progress. more »

Developing new business contacts is often time-consuming and costly. For this reason BIOTECHNICA now offers an affordable and speedy way for individuals and companies to link up with potential customers, suppliers and business partners more »

In January 2009, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama’s handling of the generic biotech issue, will be the defining issue of 2009 and beyond. more »

by Simon Rowell, James & Wells Intellectual Property

Website: James & Wells Intellectual Property

Introduction

A licence is permission to do something that would, in the absence of permission, infringe intellectual property rights. It is different to an assignment, which is a transfer of ownership of the intellectual property more »

Although the credit crunch has left non-financial services companies, including those in the biotechnology industry, without cheap debt, the pharmaceutical industry avoided relying on this resource and has remained cash-rich. As a result, pharmaceutical companies should weather the financial storm and be able to make significant acquisitions, unlike their biotechnology counterparts. more »

By Jeremy Philips  more »

by Lorin Brennan

A growing share of commerce in today’s global information economy revolves around IP assets rather than the physical commodities that dominated the industrial age. more »